The American Journal of Pharmacy Benefits | May/June 2014

Drug Trends

As we shift the healthcare paradigm, new ways to lower costs and improve adherence are worth another look.

From the Editor

There are 10 steps that need to be taken to help payers more adequately address the problem of inappropriate prescribing of pain medications.

Original Research

Executive-level pharmacy leaders in US managed care organizations identify how healthcare reform is driving changes in pharmacy benefit management.
This study is an evaluation of the dosing patterns of ustekinumab among patients with psoriasis in a real-world setting.

Patient Advocacy

Congress has passed a law designed to get advanced diagnostic tests to patients more quickly and to promote personalized care for patients.

Specialty Healthcare Benefits Council

The 2014 CMS Coverage Determination and Appeals audit will challenge plans providing Medicare Part D services, and could lead to a cascading impact much larger than audit failure alone.


We characterized the direct cost of stage 4 non-small cell lung cancer from 2000 to 2009, with a focus on drug treatments.
This study compares the initiation of asthma therapies in a real-world population.
Controlling for baseline characteristics, saxagliptin patients had lower medical costs compared with sulfonylurea patients, and lower medical and total costs than sitagliptin patients.
This model analysis explores the budget impact of prescribing single-pill fixed dose versus loose-dose combination triple therapies for hypertension.

More issues

Diabetes Compendium
Oncology Compendium